{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:58:35Z","timestamp":1770314315941,"version":"3.49.0"},"reference-count":15,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":732,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Mass Spectrometry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clinms.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T10:52:41Z","timestamp":1549104761000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report"],"prefix":"10.21627","volume":"12","author":[{"given":"Ana","family":"\u0160kari\u010di\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Zeku\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Fumi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunja","family":"Rogi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Uroi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijela","family":"Petkovi\u0107 Ramad\u017ea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"\u017digman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Bari\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4811","reference":[{"issue":"3","key":"10.1016\/j.clinms.2019.01.005_b0005","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1542\/peds.103.3.675","article-title":"Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure","volume":"103","author":"Croffie","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinms.2019.01.005_b0010","article-title":"Newborn screening for tyrosinemia type I: further evidence that succinylacetone determination on blood spot is essential","author":"la Marca","year":"2011","journal-title":"JIMD Rep."},{"key":"10.1016\/j.clinms.2019.01.005_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0599-z","article-title":"Newborn screening for tyrosinemia type 1 using succinylacetone \u2013 a systematic review of test accuracy","author":"Stinton","year":"2017","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.clinms.2019.01.005_b0020","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2008.103200","article-title":"Enhancing newborn screening for tyrosinemia type I","author":"Pass","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinms.2019.01.005_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2012.04.007","article-title":"Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine","author":"Metz","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.clinms.2019.01.005_b0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1373\/clinchem.2007.101949","article-title":"Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots","volume":"54","author":"Turgeon","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinms.2019.01.005_b0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1750-1172-4-28","article-title":"A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report","volume":"4","author":"Cassiman","year":"2009","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.clinms.2019.01.005_b0040","unstructured":"L. Sniderman King, C. Trahms, C.R. Scott, Tyrosinemia type 1, 2006 Jul 24 (updated 2017 May 25), in: M.P. Adam, H.H. Ardinger, R.A. Pagon, et al., (Eds.), GeneReviews\u00ae (Internet), Seattle (WA): University of Washington, Seattle, 1993\u20132018."},{"issue":"10","key":"10.1016\/j.clinms.2019.01.005_b0045","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1073\/pnas.74.10.4641","article-title":"On the enzymic defects in hereditary tyrosinemia","volume":"74","author":"Lindblad","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.clinms.2019.01.005_b0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJM199002153220704","article-title":"Neurologic crises in hereditary tyrosinemia","volume":"322","author":"Mitchell","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinms.2019.01.005_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2017.101","article-title":"Diagnosis and treatment of tyrosinemia type 1: a US and Canadian consensus group review and recommendations","author":"Chinsky","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.clinms.2019.01.005_b0060","first-page":"43","article-title":"Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1","volume":"19","author":"Angileri","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.clinms.2019.01.005_b0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/(SICI)1098-1004(1996)7:3<239::AID-HUMU8>3.0.CO;2-5","article-title":"Fumarylacetoacetase mutations in tyrosinaemia type I","volume":"7","author":"Rootwelt","year":"1996","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.clinms.2019.01.005_b0070","first-page":"302","article-title":"Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean","volume":"47","author":"De Braekeleer","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.clinms.2019.01.005_b0075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200666060-00002","article-title":"Nitisinone in the treatment of hereditary tyrosinaemia type 1","volume":"66","author":"McKiernan","year":"2006","journal-title":"Drugs"}],"container-title":["Clinical Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237699981830028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237699981830028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:47:37Z","timestamp":1770263257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S237699981830028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":15,"alternative-id":["S237699981830028X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinms.2019.01.005","relation":{},"ISSN":["2376-9998"],"issn-type":[{"value":"2376-9998","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report","name":"articletitle","label":"Article Title"},{"value":"Clinical Mass Spectrometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinms.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}